Lionco Pharm Grp Co Ltd (603669) — Working Capital to Net Assets Ratio
Lionco Pharm Grp Co Ltd (603669) has a Working Capital to Net Assets ratio of 11.1% as of March 2026. Working capital of CN¥69.40 Million (current assets of CN¥541.98 Million minus current liabilities of CN¥472.57 Million) is measured against net assets of CN¥623.24 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Lionco Pharm Grp Co Ltd (603669) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Lionco Pharm Grp Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Lionco Pharm Grp Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 11.1%, reflecting working capital of CN¥69.40 Million against net assets of CN¥623.24 Million CNY. Check 603669 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Lionco Pharm Grp Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Lionco Pharm Grp Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 603669 market cap.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 7.5% | CN¥46.80 Million | CN¥620.28 Million | CN¥525.38 Million | CN¥478.58 Million | ▼ -40.2 pp |
| 2024 | 47.7% | CN¥367.30 Million | CN¥769.76 Million | CN¥586.61 Million | CN¥219.31 Million | ▼ -20.9 pp |
| 2023 | 68.6% | CN¥638.42 Million | CN¥931.04 Million | CN¥881.53 Million | CN¥243.11 Million | ▼ -4.5 pp |
| 2022 | 73.1% | CN¥829.62 Million | CN¥1.14 Billion | CN¥1.13 Billion | CN¥302.42 Million | ▼ -5.0 pp |
| 2021 | 78.1% | CN¥1.14 Billion | CN¥1.46 Billion | CN¥1.79 Billion | CN¥648.85 Million | ▼ -10.2 pp |
| 2020 | 88.3% | CN¥1.31 Billion | CN¥1.48 Billion | CN¥2.04 Billion | CN¥731.57 Million | ▲ +25.5 pp |
| 2019 | 62.8% | CN¥825.36 Million | CN¥1.31 Billion | CN¥1.23 Billion | CN¥400.70 Million | ▲ +3.2 pp |
| 2018 | 59.7% | CN¥822.09 Million | CN¥1.38 Billion | CN¥1.33 Billion | CN¥504.37 Million | ▼ -1.3 pp |
| 2017 | 61.0% | CN¥792.10 Million | CN¥1.30 Billion | CN¥1.13 Billion | CN¥340.06 Million | ▼ -1.7 pp |
| 2016 | 62.6% | CN¥732.37 Million | CN¥1.17 Billion | CN¥893.10 Million | CN¥160.73 Million | ▼ -3.2 pp |
| 2015 | 65.9% | CN¥737.29 Million | CN¥1.12 Billion | CN¥944.38 Million | CN¥207.09 Million | ▲ +61.5 pp |
| 2014 | 4.4% | CN¥16.48 Million | CN¥374.13 Million | CN¥184.27 Million | CN¥167.79 Million | ▼ -11.0 pp |
| 2013 | 15.4% | CN¥54.15 Million | CN¥351.02 Million | CN¥269.56 Million | CN¥215.41 Million | ▼ 0.0 pp |
| 2012 | 15.4% | CN¥36.47 Million | CN¥236.22 Million | CN¥160.50 Million | CN¥124.02 Million | ▼ -3.1 pp |
| 2011 | 18.6% | CN¥23.86 Million | CN¥128.55 Million | CN¥136.77 Million | CN¥112.91 Million | — |